|
AUPO755097A0
(en)
*
|
1997-06-25 |
1997-07-17 |
University Of Queensland, The |
Receptor agonist and antagonist
|
|
AUPQ339899A0
(en)
|
1999-10-13 |
1999-11-04 |
University Of Queensland, The |
Novel molecules
|
|
ES2353077T3
(es)
|
2000-08-10 |
2011-02-25 |
Mitsubishi Tanabe Pharma Corporation |
Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
|
|
CN102050758A
(zh)
|
2000-09-14 |
2011-05-11 |
田边三菱制药株式会社 |
酰胺衍生物及其制备药物的用途
|
|
AUPR833401A0
(en)
*
|
2001-10-17 |
2001-11-08 |
University Of Queensland, The |
G protein-coupled receptor antagonists
|
|
EP1492811B1
(en)
|
2002-03-19 |
2011-09-21 |
Cincinnati Childrens's Hospital Medical Center |
Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin
|
|
US20040014782A1
(en)
*
|
2002-03-29 |
2004-01-22 |
Krause James E. |
Combination therapy for the treatment of diseases involving inflammatory components
|
|
AUPS160602A0
(en)
*
|
2002-04-08 |
2002-05-16 |
University Of Queensland, The |
Therapeutic method
|
|
AU2002950657A0
(en)
|
2002-08-08 |
2002-09-12 |
Alchemia Limited |
Derivatives of monosaccharides for drug discovery
|
|
AU2002951995A0
(en)
*
|
2002-10-11 |
2002-10-31 |
Alchemia Limited |
Classes of compounds that interact with gpcrs
|
|
AU2003266858B2
(en)
*
|
2002-10-11 |
2006-09-14 |
Vast Bioscience Pty Limited |
Classes of compounds that interact with GPCRs
|
|
AU2002952086A0
(en)
*
|
2002-10-16 |
2002-11-07 |
The University Of Queensland |
Treatment of osteoarthritis
|
|
US7410945B2
(en)
*
|
2002-10-16 |
2008-08-12 |
The University Of Queensland |
Treatment of inflammatory bowel disease
|
|
AU2002952129A0
(en)
*
|
2002-10-17 |
2002-10-31 |
The University Of Queensland |
Treatment of hypersensitivity conditions
|
|
AU2003902354A0
(en)
*
|
2003-05-15 |
2003-05-29 |
Harkin, Denis W. |
Treatment of haemorrhagic shock
|
|
AU2003902586A0
(en)
*
|
2003-05-26 |
2003-06-12 |
The University Of Queensland |
Treatment of burns
|
|
WO2005014849A2
(en)
*
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
EP1498422A1
(de)
*
|
2003-07-17 |
2005-01-19 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
WO2006037159A1
(en)
*
|
2004-10-04 |
2006-04-13 |
Alchemia Limited |
Selective inhibitors
|
|
AU2006205830A1
(en)
*
|
2005-01-17 |
2006-07-20 |
Jerini Ag |
C5a receptor antagonists
|
|
US20090117171A1
(en)
*
|
2005-03-11 |
2009-05-07 |
Cedric Francois |
Compositions and methods for treatment of macular degeneration and related conditions
|
|
EP1739078A1
(de)
|
2005-05-30 |
2007-01-03 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
EP2148691B1
(en)
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
|
WO2009015087A2
(en)
*
|
2007-07-20 |
2009-01-29 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for treatment of trauma
|
|
US20110190221A1
(en)
*
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
EP2304809A2
(en)
*
|
2008-07-02 |
2011-04-06 |
Saint-Gobain Performance Plastics Chaineux |
Framed device, seal, and method for manufacturing same
|
|
RS64039B1
(sr)
|
2008-11-10 |
2023-04-28 |
Alexion Pharma Inc |
Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
|
|
EP2525814A4
(en)
*
|
2010-01-22 |
2013-09-11 |
Univ Louisville Res Found |
METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES
|
|
KR101800913B1
(ko)
|
2010-04-30 |
2017-12-20 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항-c5a 항체들과 이 항체들을 이용하는 방법
|
|
US9895411B2
(en)
|
2010-06-29 |
2018-02-20 |
San Diego State University Research Foundation |
Analogs of C5a and methods of using same
|
|
EP2468295A1
(en)
*
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Vaccines based on peptides of the complement protein C5a
|
|
CN103796667A
(zh)
|
2011-06-22 |
2014-05-14 |
艾普莱斯制药公司 |
用补体抑制剂治疗慢性障碍的方法
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
WO2014043223A1
(en)
*
|
2012-09-11 |
2014-03-20 |
Hospital For Special Surgery |
Irhom2 inhibition for the treatment of complement mediated disorders
|
|
CA2891673C
(en)
|
2012-11-15 |
2025-10-07 |
Apellis Pharmaceuticals Inc |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
JP2016516752A
(ja)
*
|
2013-04-02 |
2016-06-09 |
ザ スクリプス リサーチ インスティテュート |
アテローム性動脈硬化症の治療および予防のための環状ペプチドの使用
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
JP6968787B2
(ja)
|
2015-10-07 |
2021-11-17 |
アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. |
投与レジメン
|
|
EP3491005A1
(en)
|
2016-07-29 |
2019-06-05 |
Pfizer Inc |
Cyclic peptides as c5 a receptor antagonists
|
|
US20200057046A1
(en)
|
2016-10-27 |
2020-02-20 |
Alexion Pharmaceuticals, Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
|
PL3411400T3
(pl)
|
2017-04-03 |
2021-12-20 |
Inflarx Gmbh |
Leczenie chorób zapalnych za pomocą inhibitorów aktywności c5a
|
|
US11040107B2
(en)
|
2017-04-07 |
2021-06-22 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
JP7502865B2
(ja)
|
2017-06-23 |
2024-06-19 |
インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
|
|
KR20240167712A
(ko)
|
2017-12-15 |
2024-11-27 |
아펠리스 파마슈티컬스 인코포레이티드 |
투여 요법 및 관련 조성물 및 방법
|
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
AU2020438234A1
(en)
|
2020-03-27 |
2022-09-29 |
Inflarx Gmbh |
Inhibitors of C5a for the treatment of corona virus infection
|
|
WO2021231720A1
(en)
|
2020-05-15 |
2021-11-18 |
Alexion Pharmaceuticals, Inc. |
Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
|
|
WO2024238421A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of biomarkers for the identification and treatment of complement-mediated disorders
|
|
WO2024238422A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
|
|
US12180274B2
(en)
|
2023-05-26 |
2024-12-31 |
Inflarx Gmbh |
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
|